Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen in Locally Advanced Pancreatic Adenocarcinoma
NCT05494697Phase 2Suspended
- Sponsor
- AIM ImmunoTech
- Start
- Aug 2027
- Primary completion
- Feb 2031
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod in pancreatic adenocarcinoma (PDAC), sponsored by AIM ImmunoTech. Planned start Aug 2027; status: suspended.
02
Drugs
rintatolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05494697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494697.